





threatens the lives of 450 million people across 26 countries in Africa’s “Menin-
gitis Belt,” mostly children and young adults.
THOUSANDS DIE in years with large outbreaks.
1 in 10 die within 2 days even when antibiotics are available. 
1 in 4 survivors are left with permanent disabilities such as paralysis, blindness, 
hearing loss, seizures, and intellectual disability.
MENINGITIS treatment is costly for both families and nations and contributes 
to the cycle of poverty.
Each case of meningitis in a family results in a sudden cost of about $90—what 
is about 3 or 4 months of the family’s income.
The permanent disabilities caused by meningitis leave survivors less able to care 
for themselves and less likely to earn income.
The MenAfriVac® vaccine 
protects against meningitis A...
saving lives and money
MenAfriVac® became available for use in Africa in 2010 priced at just $0.40 per 
dose. Over 217 million people had received the vaccine by the end of 2014.
A prevention cost of $0.40 per person vs. a treatment cost of  $90 per person.
The vaccine is targeted to protect 450 million people at risk from meningitis by 
2016 and save nearly 150,000 lives.
MenAfriVac® is the first vaccine for use in Africa that can be transported and 
stored for as long as 4 days without refrigeration or even an ice pack. This saves 
money and allows for safe delivery to people in even the most remote areas.
The introduction of this vaccine is a giant step toward achieving elimination of 
epidemic meningitis as a public health problem in sub-Saharan Africa.
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